Restricted accessResearch articleFirst published online 1993-02
New Prospects for the Treatment of Raynaud's Phenomenon Using A Serotoninergic S2 Receptor Antagonist (Ketanserin) and Stable Derivatives of Prostacyclin
The authors propose a promising new therapy for the treatment of Raynaud's phenomenon, with parenteral prostacyclin (carbaprostacycline) and a serotonergic S2-receptor antagonist (ketanserin) given orally. They studied 31 patients, 22 treated with ketanserin and carbaprostacycline, 9 with carbaprostacycline alone. Both groups demonstrated successful results and a significant improvement in measurements performed by photoplethysmography and transcutaneous pulse oxymetry.
Get full access to this article
View all access options for this article.
References
1.
Lewis T.: Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud's disease. Heart15:7-101, 1929.
2.
Cohen RA, Coffman JD: Reduced fingertip arterial pressure in Raynaud's disease. J Vasc Med Biol1:21-26, 1989.
3.
Nielsen SL: Raynaud phenomena and finger systolic pressure during cooling. Scand JLab Invest38:765-770, 1978.
4.
Keenan EJ, Porter JM: Alpha-2 adrenergic receptors in platelets from patients with Raynaud's syndrome . Surgery94:204-209, 1983.
5.
Edward JM, Phinney ES, Taylor LM Jr: Alpha-2 adrenergic receptor in obstructive and spastic Raynaud syndrome. J Vasc Surg5:38-45, 1987.
6.
Pola P., Savi L., Dal Lago A., et al: Invariability of blood viscosity after cold testing in patients suffering for Raynaud's disease. J Cardiovasc Surg21:211-214, 1980.
7.
Stranden E., Roald OK, Krohg K.: Treatment of Raynaud's phenomenon with the 5-HT2 receptor antagonist ketanserin . Br Med J285:1069-1071, 1982 .
8.
Savi L., Pola P., Dal Lago A., et al: Ca-antagonist drugs for the study and treatment of angiospastic syndromes. Proc XIth International Congress of Angiology, Prague, 1978. In: Adaptability of Vascular Wall, Springer-Verlag, 1980, pp 546-548.
9.
Coffman JD, Cohen RA: Serotoninergic vasoconstriction in human fingers during reflex sympathetic response to cooling. Am J Physiol254:H889-H893, 1988.
10.
Coffman JD, Clement DL, Creager MA: International study of ketanserin in Raynaud's phenomenon. Am J Med87:264-268, 1989.
11.
Dowd PM, Martin Mfr, Cooke ED: Treatment of Raynaud's phenomenon by intravenous infusion of prostacyclin (PGI2). Br J Dermatol106:81-89, 1982.
12.
Coffman JD: Pathogenesis and treatment of Raynaud's phenomenon. CardivascDrug Ther4:45-51, 1990.
13.
Belch Jjf, Drury JK, Capell H.: Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's phenomenon. Lancet1:313-315, 1983.
14.
Smith EF III, Gallenkamper W. , Beckman R., et al: Early and late administration of PGI 2-analogue, ZK36374 (Iloprost): Effects on myocardial preservation, collateral blood flow, and infarct size. Cardiovasc Res18:163-173, 1984.
15.
Schror K., Verheggen R.: Prostacyclin are only weak antagonists of coronary vasospasm induced by authentic thromboxane A2 and serotonin. J Cardivasc Pharmacol
16.
Musial J., Wilczynska M., Sladek K., et al: Fibiynolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostagladins3:61-70, 1986.
17.
Blunt RJ, George AJ, Hurlow RA, et al: Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome. Br J Haematol45:651-658, 1980.
